The Future of IL-1 Targeting in Kidney Disease

AFŞAR B., COVİC A., ORTİZ A., Afsar R. E., Kanbay M.

DRUGS, vol.78, no.11, pp.1073-1083, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 78 Issue: 11
  • Publication Date: 2018
  • Doi Number: 10.1007/s40265-018-0942-2
  • Journal Name: DRUGS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1073-1083
  • Süleyman Demirel University Affiliated: Yes

Abstract

Interleukin (IL)-1 alpha and IL-1 beta are proinflammatory cytokines that play a role in many diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and periodic inflammatory syndromes, including familial Mediterranean fever and Muckle-Wells syndrome. Drugs targeting IL-1 such as recombinant IL-1Ra (anakinra), neutralizing anti-IL-1 beta antibodies (canakinumab) and IL-1 beta traps (rilonacept) are in clinical use to treat these diseases. Additionally, experimental evidence suggests a role of IL-1 in kidney disease and hypertension and targeting IL-1 showed promising results in high cardiovascular risk patients, hemodialysis and renal transplantation patients. We now summarize knowledge on the potential role of IL-1 targeting in patients with kidney disease.